Surgical robotics company, CMR Surgical, has today announced the appointment of Chris Weatherall as Chief Quality and Regulatory Officer (CQRO) and Bertrand Weil as Chief Business Development Officer (CBDO), strengthening the Company’s leadership team as it continues with its global expansion and commercial scale-up.
Chris Weatherall is a regulatory and quality expert with over 30 years’ experience working at leading healthcare organisations. Chris joins from Phillips RDT where he was Director of Quality Assurance and Regulatory Affairs and sat on the senior leadership team. He has also held senior quality and regulatory positions at Meridian Bioscience International where he was Vice President of Quality and Regulatory Affairs for the lifescience division. As CQRO at CMR, he will lead global regulatory strategy and execution, as well as overseeing quality assurance across CMR’s products and services.
Bertrand Weil is a highly experienced executive with a successful career in business strategy and corporate development for healthcare companies spanning almost two decades. Bertrand joins CMR from Mölnlycke, Investor AB’s wholly-owned medical solutions business, where he was most recently Vice President, Corporate Strategy and Business Development. At Mölnlycke, he strengthened the company’s core Wound Care and Surgical Franchises through a series of acquisitions and partnerships, as well as creating platforms for new areas of future growth. Prior to this, Bertrand spent nearly a decade at GE Healthcare in finance and corporate development roles, as part of the group providing inorganic leadership for General Electric’s Healthcare business. As CBDO, he will lead CMR’s business development activities as Versius is introduced into new markets globally.
These appointments further broaden the expertise of CMR’s leadership team, following a number of hires including Barrington D’Arcy as Chief Operations Officer from Space X last year, and strengthens business and regulatory operations following the Company’s record $600 million (£425 million) Series D financing in June 2021.
Per Vegard Nerseth, Chief Executive Officer of CMR Surgical, commented: “The appointment of Chris and Bertrand is timely and a reflection of the maturity of the business as a global medical devices company. Such experienced individuals will help us to continue to deliver a high-quality system and meet our wider business objectives. Bertrand and Chris are executives with experience in companies across the life science sector, and we look forward to benefiting from their talents and insight as the Company continues to grow.”
Chris Weatherall, Chief Quality and Regulatory Officer of CMR Surgical, commented: “CMR’s vision is for minimally invasive robotic surgery to be made accessible to surgeons and patients worldwide. I’m proud to be leading the continued regulatory progress of the Versius system, whilst ensuring quality across all of our product and services.”
Bertrand Weil, Chief Business Development Officer of CMR Surgical, commented: “Versius represents an outstanding innovation in the surgical robotics space, providing surgeons with an unparalleled level of versatility. I’m excited to work with the team to guide business development globally, and to capitalise on CMR’s potential to become a market leader by making minimal access surgical robotics more broadly available.”